Cargando…

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future

Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant prescription. More than ten antidepressants (including tricyclics, selective serotonin reuptake inhibitors and venlafaxine) have already genetic biomarkers of response/side effects in clinical guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fabbri, Chiara, Serretti, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean College of Neuropsychopharmacology 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006978/ https://www.ncbi.nlm.nih.gov/pubmed/31958900 http://dx.doi.org/10.9758/cpn.2020.18.1.1

Ejemplares similares

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

Post-traumatic stress disorder and childhood emotional abuse are markers of subthreshold bipolarity and worse treatment outcome in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2021)

Anhedonia and Depressive Disorders
por: Serretti, Alessandro
Publicado: (2023)

Pharmacogenetics and Depression: A Critical Perspective
por: Corponi, Filippo, et al.
Publicado: (2019)

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder
por: Bartova, L., et al.
Publicado: (2022)

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression
por: Fabbri, Chiara
Publicado: (2016)

The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants
por: Serretti, Alessandro
Publicado: (2018)

Clinical Utility of Fluid Biomarker in Depressive Disorder
por: Serretti, Alessandro
Publicado: (2022)

Clinical correlates and prognostic implications of severe suicidal ideation in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2023)

Antidepressant emergent mood switch in major depressive disorder: onset, clinical correlates and impact on suicidality
por: Olgiati, Paolo, et al.
Publicado: (2023)

Major depressive disorder: Validated treatments and future challenges
por: Karrouri, Rabie, et al.
Publicado: (2021)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing
por: Fabbri, Chiara, et al.
Publicado: (2021)

Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs
por: Kato, M, et al.
Publicado: (2015)

Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors
por: Mandelli, Laura, et al.
Publicado: (2016)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder
por: Olgiati, Paolo, et al.
Publicado: (2022)

Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank
por: Fabbri, Chiara, et al.
Publicado: (2023)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample
por: Calabrò, Marco, et al.
Publicado: (2018)

A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
por: Lee, Kyung Ho, et al.
Publicado: (2021)

The genetic basis of major depressive disorder
por: Flint, Jonathan
Publicado: (2023)

Rediscovering Trazodone for the Treatment of Major Depressive Disorder
por: Fagiolini, Andrea, et al.
Publicado: (2012)

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives
por: Shin, Cheolmin, et al.
Publicado: (2020)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases
por: Serretti, Alessandro, et al.
Publicado: (2007)

Abelson Helper Integration Site-1 Gene Variants on Major Depressive Disorder and Bipolar Disorder
por: Porcelli, Stefano, et al.
Publicado: (2014)

Treatment of Major Depressive Disorder in Pediatric Populations
por: Neavin, Drew R., et al.
Publicado: (2018)

The Genetics of Major Depression
por: Flint, Jonathan, et al.
Publicado: (2014)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh, Mandeep, et al.
Publicado: (2012)

Sheehan’s Syndrome Presenting as Major Depressive Disorder
por: Qadri, Mehmood I, et al.
Publicado: (2015)

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?
por: Lippi, Matteo, et al.
Publicado: (2022)

Clinical specificity profile for novel rapid acting antidepressant drugs
por: Scala, Mauro, et al.
Publicado: (2023)

Pharmacological Treatment of Major Depressive Disorder in Adolescents
por: Farley, Rachel L.
Publicado: (2005)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uc3ntqg34tg98ap4afad87hdid